In the phase III clinical trial investigating the treatment of advanced metastatic renal cell carcinoma patients with PD-1 inhibitor nivolumab, researchers used the PD-L1 protein expression of tumor cells as a predictive molecular marker, which showed that patients can still benefit from immunotherapy when the expression level of PD-L1 is lower [48]. Here, CD274 is linked to neoplasm.